Primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome

disease
On this page

Summary

Primary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome (MONDO:0034189) is a disease. A subtype of cholangitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: Unknown (Worldwide) [Orphanet-validated]
  • Phenotypes (HPO): 36

Clinical features

Signs & symptoms

Clinical features (HPO)

36 HPO clinical features (Orphanet curated; top 36 by frequency):

HPO IDTermFrequency
HP:0030057Autoimmune antibody positivityVery frequent (80-99%)
HP:0032220Interface hepatitisVery frequent (80-99%)
HP:0000989PruritusFrequent (30-79%)
HP:0002910Elevated circulating hepatic transaminase concentrationFrequent (30-79%)
HP:0003237Increased circulating IgG levelFrequent (30-79%)
HP:0003493Antinuclear antibody positivityFrequent (30-79%)
HP:0011040Abnormality of the intrahepatic bile ductFrequent (30-79%)
HP:0012378FatigueFrequent (30-79%)
HP:0033562Anti-glycoprotein-210 antibody positivityFrequent (30-79%)
HP:0034093Anti-Ro52/TRIM21 antibody positivityFrequent (30-79%)
HP:0034107Anti-p53 antibody positivityFrequent (30-79%)
HP:0034108Anti-Y-box protein-1 antibody positivityFrequent (30-79%)
HP:0034110Anti-Gerbich phenotype 1 antibody positivityFrequent (30-79%)
HP:0034111Anti-MIT3 antibody positivityFrequent (30-79%)
HP:0034114Anti-hexokinase-1 antibody positivityFrequent (30-79%)
HP:0034115Anti-Kelch like protein 12 antibody positivityFrequent (30-79%)
HP:0034155Anti-sp100 antibody positivityFrequent (30-79%)
HP:0100889Abnormality of the ductus choledochusFrequent (30-79%)
HP:0001394CirrhosisOccasional (5-29%)
HP:0001396CholestasisOccasional (5-29%)
HP:0002037Inflammation of the large intestineOccasional (5-29%)
HP:0002611Cholestatic liver diseaseOccasional (5-29%)
HP:0002829ArthralgiaOccasional (5-29%)
HP:0002904HyperbilirubinemiaOccasional (5-29%)
HP:0003155Elevated circulating alkaline phosphatase concentrationOccasional (5-29%)
HP:0003262Smooth muscle antibody positivityOccasional (5-29%)
HP:0003496Increased circulating IgM levelOccasional (5-29%)
HP:0025344Interlobular bile duct destructionOccasional (5-29%)
HP:0030167Antimitochondrial antibody positivityOccasional (5-29%)
HP:0030909Anti-liver cytosolic antigen type 1 antibody positivityOccasional (5-29%)
HP:0030948Elevated gamma-glutamyltransferase levelOccasional (5-29%)
HP:0030988Granulomatous cholangitisOccasional (5-29%)
HP:0030991Sclerosing cholangitisOccasional (5-29%)
HP:0032252GranulomaOccasional (5-29%)
HP:0100279Ulcerative colitisOccasional (5-29%)
HP:0030908Liver kidney microsome type 1 antibody positivityVery rare (<1-4%)

Identifiers

Disease identifiers

FieldValue
Canonical nameprimary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome
Mondo IDMONDO:0034189
Orphanet562639
UMLSC5680117
MedGen1812237
GARD0022250
Is cancer (heuristic)no

Disease family

This is a subtype of cholangitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorderhepatobiliary disorderbiliary tract disorderbile duct disordernon-neoplastic bile duct disordercholangitisprimary biliary cholangitis/primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome

Related subtypes (8): suppurative cholangitis, ascending cholangitis, acute cholangitis, pericholangitis, cholecystitis, chronic cholangitis, sclerosing cholangitis, autoimmune cholangitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.